



**Therapies for major infectious
diseases and related cancers**

Julie Phillips, CEO


www.biodiem.com

(ASX:BDM)

Australian Life Science Investment Showcase


15 June 2012, New York.

A compelling investment case




BioDiem has an extensive technology portfolio targeting multiple infectious diseases and cancers, supported by:

- Existing license income with strong growth
- Existing licenses to WHO, Serum Institute of India & Changchun BCHO Biotech Co, China



A strong pipeline of products with high value disease targets, including:

- Large markets: influenza, schistosomiasis, hepatitis, TB
- High value niche markets: fungal diseases, MRSA, sexually transmitted diseases, viral-related cancers
- Influenza vaccine on the market



Global network with leading research institutions and companies

- Including WHO, National Institutes of Health (USA), PATH (Program for Appropriate Technology in Health), Centres for Disease Control and Prevention (US), VIVALIS and the Institute of Experimental Medicine
- Partnering strategy accelerates development, lowers cost, while retaining IP control

Multiple products targeting multiple diseases



Product	Disease Targets	Current Partners	Development Status
LAIV Vaccine (Influenza)	Influenza – Seasonal & Pandemic	WHO SII (India) BCHT (China) IEM (Russia)	Marketed with license revenues of A\$1.4m ytd Phase II (cell-based production technology)
	Bird flu	IEM/WHO	Clinical trial commenced in Russia
LAIV Vector (Vaccine delivery)	Vaccine development	VIVALIS	First stage of development project underway
BDM-I (Antimicrobial)	Bacterial infections (MRSA, tuberculosis)	US government backed research institutions	Success in activity screening program
	Fungal infections (aspergillus, scedosporium, yeasts and others)	US government backed research institutions University of Sydney	Positive screening results in difficult to treat fungi, patents granted for major indications
	Parasitic diseases (schistosomiasis, others)	QIMR program	Success in activity screening program
SAVINE (Custom vaccines)	Nasopharyngeal carcinoma (NPC), tuberculosis	In-house	Seeking partner for more advanced data in animals
BDM-E (eye disease)	RP (orphan eye disease)	Foundation Fighting Blindness University of Miami	Animal model data support activity in retinal disease, safety shown at doses used (in Phase I/II study)
New vaccine technology	Dengue fever, hepatitis, various targets	Australian Universities	Promising early-stage laboratory results

A growing business in flu vaccines



- **Current major revenue generator and growth business**
- **LAIV licensed to WHO as part of Global Pandemic Influenza Action Plan**
- **BioDiem has signed sublicenses with Serum Institute of India Ltd (SII), and Changchun BCHT Biotechnology Co. (BCHT) of China**
 - ✓ H1N1 (pandemic) influenza vaccine launched in India by SII in July 2010 (Nasovac™).
 - Exclusive licence signed with Serum Institute of India for private sector sales in India
 - ✓ Currently in production for seasonal influenza
 - ✓ Non-exclusive license signed with Serum Institute for Mexico, Argentina, Peru, South Africa, Bangladesh, Bhutan, Nepal, Pakistan and Sri Lanka.
 - ✓ BCHT deal for Chinese private sector market signed in February 2012

YTD flu vaccine licensing revenue of A\$1.4 million


Versatile proprietary platform technologies



- Opportunity to target multiple infectious diseases and related cancers
- Licensing model to be pursued targeting other vaccine developers
- Complementary technologies acquired, broadening disease target range

LAIV Vector: A viral vector can deliver a customised protein into the body to produce a **Protective or Boosted** immune response to fight a disease e.g. nasopharyngeal cancer.

SAVINE: the “scrambled antigen vaccine” technology allows design of customised proteins e.g. NPC SAVINE for Epstein Barr virus-related diseases.



One in six cancers is linked to a virus infection

BDM-I broad spectrum antimicrobial



- BDM-I's broad activity could mean claiming a share of **several major** markets
- Microorganisms being targeted include **bacteria, fungi, and parasites**
- **Increasing resistance** to antibiotics is a major concern for healthcare systems worldwide
- Significant opportunity to target **high value** diseases
- Big Pharma are returning to this space, and looking to acquire
- Pipelines are running dry – innovative products are in high demand

Next steps: An accelerated development program with rapid market Access for life-threatening diseases

Eye diseases

BioDiem

Tackling genetic eye disease

A pre-packaged asset for sale

- **FDA granted Orphan Drug status** to BDM-E compound for treatment of genetic eye disease *retinitis pigmentosa (RP)*
- BioDiem's studies show BDM-E has biological effect in inflammation and eye disease models. New intellectual property generated from these studies
- **Clinical usage:** no safety concerns at dosage used
- Results will be presented in July 2012 at International eye research conference
- Research collaboration with Uni of Miami and Foundation Fighting Blindness to evaluate the potential of BDM-E to treat retinitis pigmentosa
- The study will examine the protective ability of BDM-E in a non-clinical disease model which mimics RP.

Next Steps: Completion of data package.
On track for sale or out license within 12 months

Why invest in BioDiem?



- BioDiem has successfully **licensed its influenza vaccine** to the largest markets in the world
- A proven track record of **new license growth**, e.g. BCHT (China) and the Serum Institute of India
- Exposure to multiple exciting **opportunities for disease treatments** with high market need
- **Global partnering strategy** with research leaders accelerates development and delivers more for each research and development dollar
- Potential to engineer **multiple new vaccines** from BioDiem's technologies
- The research suggests **exciting potential for BDM-I** in multiple acute and chronic infectious diseases with a chance for accelerated regulatory approval



**Therapies for major infectious
diseases and related cancers**

Julie Phillips, CEO

www.biodiem.com

(ASX:BDM)

Australian Life Science Investment Showcase

15 June 2012, New York.